Proactive Investors - Run By Investors For Investors

Cello Health 'making good headway' with decent organic growth

Mark Scott, chief executive of Cello Health plc (LON:CLL) tells Proactive Investors they enjoyed a good rise in half-year profits, driven by another six months of strong growth from its Cello Health division.

The company has two arms: Health, which provides expertise, processes, intellectual property and market knowledge spanning the pharmaceutical, biotechnology, diagnostics, healthcare equipment and consumer health sectors.

And Signal, which provides “digital, social media and branding expertise” to companies. This division used to be focused sectors such as technology and retail, but it has taken a much greater interest in health of late.

 
Meet Clinigen Group PLC, MaxCyte, Cello Health PLC, Oncimmune and Silence Therapeutics PLC at our event, London , 11 July 2019. Register here »
View full CLL profile View Profile

Cello Health PLC Timeline

Video
April 11 2019
Big Picture
March 22 2019

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use